All HHS Contracts — April 30, 2026

$100,289,100 obligation (potential $221M with options) under firm fixed price for hazardous waste disposal services, with $24.7M outlayed to date through 2026-09-24 performance period.

$150,780,000 cost no fee obligation (potential $285.8M) for CARB-X antibacterial accelerator R&D, with $75.5M outlayed and 107 subawards totaling $63.7M through 2029 (potential 2032).

INMAR RX SOLUTIONS INC faces high firm fixed price execution risk on $100.3M HHS ASPR medical waste contract amid partial $24.7M outlays to date.

Trustees of Boston University, as nonprofit, derives no profit margins from $150.8M cost no fee HHS BARDA R&D award despite stable funding.

INMAR RX SOLUTIONS INC option exercise could expand $100.3M HHS ASPR waste disposal contract to $221M total.

Trustees of Boston University potential extension of $150.8M HHS BARDA R&D to 2032 and full $285.8M value.

HHS BARDA funds $150.8M Trustees of Boston University antibacterial R&D (cost no fee, full competition) while ASPR commits $100.3M to INMAR RX SOLUTIONS INC for medical waste disposal (firm fixed price), signaling sustained civilian investment in biotech and environmental services.

{"entity"=>"INMAR RX SOLUTIONS INC", "reason"=>"Progress on $100.3M obligation outlays beyond $24.7M and options to $221M amid high firm fixed price risk.", "trigger"=>"option exercise, performance to 2026-09-24"}

{"entity"=>"Trustees of Boston University", "reason"=>"$150.8M BARDA R&D with $75.5M outlayed, 107 subawards at $63.7M, and options to $285.8M/2032.", "trigger"=>"remaining $75M obligation progress, option exercise"}